PHASEBIO PHARMACEUTICALS INC's ticker is PHAS and the CUSIP is 717224109.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $0 | – | 197 | 0.0% | 0.00% | – |
| Q3 2022 | $0 | – | 197 | 0.0% | 0.00% | – |
| Q2 2022 | $0 | -100.0% | 197 | -99.4% | 0.00% | – |
| Q1 2022 | $43,000 | -72.4% | 31,895 | -46.3% | 0.00% | – |
| Q4 2021 | $156,000 | +54.5% | 59,428 | +82.2% | 0.00% | – |
| Q3 2021 | $101,000 | -19.8% | 32,623 | -3.4% | 0.00% | – |
| Q2 2021 | $126,000 | +180.0% | 33,770 | +164.8% | 0.00% | – |
| Q1 2021 | $45,000 | +181.2% | 12,754 | +159.1% | 0.00% | – |
| Q4 2020 | $16,000 | -55.6% | 4,923 | -52.4% | 0.00% | – |
| Q3 2020 | $36,000 | -55.0% | 10,350 | -40.9% | 0.00% | – |
| Q2 2020 | $80,000 | +128.6% | 17,525 | +64.8% | 0.00% | – |
| Q1 2020 | $35,000 | -73.9% | 10,635 | -51.6% | 0.00% | – |
| Q4 2019 | $134,000 | +106.2% | 21,969 | +41.1% | 0.00% | – |
| Q3 2019 | $65,000 | -81.1% | 15,566 | -40.7% | 0.00% | – |
| Q2 2019 | $344,000 | +473.3% | 26,258 | +316.8% | 0.00% | – |
| Q1 2019 | $60,000 | – | 6,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Johnson & Johnson Innovation - JJDC, Inc. | 1,607,044 | $5,400,000 | 0.70% |
| NEA Management Company, LLC | 6,643,704 | $22,323,000 | 0.59% |
| DAFNA Capital Management LLC | 320,542 | $1,077,000 | 0.32% |
| Platform Technology Partners | 141,025 | $474,000 | 0.23% |
| Parkman Healthcare Partners LLC | 110,547 | $371,000 | 0.10% |
| Rock Springs Capital Management LP | 1,314,374 | $4,416,000 | 0.09% |
| GSA CAPITAL PARTNERS LLP | 140,341 | $472,000 | 0.08% |
| SABBY MANAGEMENT, LLC | 65,000 | $218,000 | 0.04% |
| Virtu Financial LLC | 28,821 | $97,000 | 0.01% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 127,600 | $429,000 | 0.01% |